Predictive Oncology Inc. (POAI) Sells 10 STREAMWAY® Systems to Prominent Teaching Hospital
October 02 2019 - 8:00AM
Predictive Oncology Inc. (NASDAQ: POAI) today announced that
its Skyline Medical division, producer of the FDA-approved and
CE-marked STREAMWAY® System for automated, direct-to-drain medical
fluid disposal, has completed the sale of ten systems to the
foremost teaching and research hospital in upstate New York.
According to U.S. News and World Report, the 800+ bed
hospital has among the best clinical programs in the country.
The sale surpasses the company’s largest single hospital sale to
date and is expected to generate 6000 procedures annually.
Skyline Medical’s patented, FDA-approved STREAMWAY System is the
first truly continuous, direct-to-drain fluid disposal system
designed specifically for medical applications such as radiology,
endoscopy, surgery, urology, and cystoscopy procedures. The system
has revolutionized the way healthcare facilities handle potentially
infectious waste by connecting directly to facilities’ plumbing
systems in order to automate the collection, measurement, and
disposal of waste fluids. This minimizes human intervention,
creating a safer system with improved compliancy with Occupational
Safety and Health Administration (OSHA) and other regulatory agency
safety guidelines (http://nnw.fm/oaC78).
Additionally, by eliminating plastic waste in the form of
canisters and evacuated bottles, the STREAMWAY System reduces
overhead costs and minimizes environmental impact, eliminating the
approximately 50 million potentially disease-infected canisters
that wind up in landfills each year in the United States
(http://nnw.fm/oQQ8d).
About Predictive Oncology Inc.
Predictive Oncology Inc. (NASDAQ: POAI) operates in two
business areas: first, applying artificial intelligence to
personalized medicine and drug discovery to provide personalized
medicine solutions for patients and clinicians as well as clients
in the pharmaceutical, diagnostic, and biotech industries, and
second, production of the FDA-approved STREAMWAY® System for
automated, direct-to-drain medical fluid disposal.
Forward-Looking Statements
Certain of the matters discussed in the press release contain
forward-looking statements that involve material risks to and
uncertainties in the Company’s business that may cause actual
results to differ materially from those anticipated by the
statements made herein. Such risks and uncertainties include (i)
risks related to the recent merger with Helomics, including the
fact that the combined company will not be able to continue
operating without additional financing; possible failure to realize
anticipated benefits of the merger; costs associated with the
merger may be higher than expected; the merger may result in
disruption of the Company’s and Helomics’ existing businesses,
distraction of management and diversion of resources; and the
market price of the Company’s common stock may decline as a result
of the merger; (ii) risks related to our partnerships with other
companies, including the need to negotiate the definitive
agreements; possible failure to realize anticipated benefits of
these partnerships; and costs of providing funding to our partner
companies, which may never be repaid or provide anticipated
returns; and (iii) other risks and uncertainties relating to the
Company that include, among other things, current negative
operating cash flows and a need for additional funding to finance
our operating plan; the terms of any further financing, which may
be highly dilutive and may include onerous terms; unexpected costs
and operating deficits, and lower than expected sales and revenues;
sales cycles that can be longer than expected, resulting in delays
in projected sales or failure to make such sales; uncertain
willingness and ability of customers to adopt new technologies and
other factors that may affect further market acceptance, if our
product is not accepted by our potential customers, it is unlikely
that we will ever become profitable; adverse economic conditions;
adverse results of any legal proceedings; the volatility of our
operating results and financial condition; inability to attract or
retain qualified senior management personnel, including sales and
marketing personnel; our ability to establish and maintain the
proprietary nature of our technology through the patent process, as
well as our ability to possibly license from others patents and
patent applications necessary to develop products; Predictive
Oncology’s ability to implement its long range business plan for
various applications of its technology; Predictive Oncology’s
ability to enter into agreements with any necessary marketing
and/or distribution partners and with any strategic or joint
venture partners; the impact of competition, the obtaining and
maintenance of any necessary regulatory clearances applicable to
applications of Predictive Oncology’s technology; and management of
growth and other risks and uncertainties that may be detailed from
time to time in the Company’s reports filed with the SEC,
which are available for review at www.sec.gov. This is not a
solicitation to buy or sell securities and does not purport to be
an analysis of Predictive Oncology’s financial position. See
Predictive Oncology’s most recent Annual Report on Form 10-K, and
subsequent reports and other filings at www.sec.gov.
Contact Bob Myers, Predictive Oncology Inc.
651-389-4800
Source: Predictive Oncology Inc.
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Sep 2023 to Sep 2024